Recent Advances of Vaccine Adjuvants for Infectious Diseases
Authors:
Open Access
- 1 January 2015
- journal article
- review article
- Published by The Korean Association of Immunobiologists in Immune Network
- Vol. 15 (2) , 51-7
Abstract
Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.Keywords
This publication has 51 references indexed in Scilit:
- Mechanisms of Action of AdjuvantsFrontiers in Immunology, 2013
- Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsionExpert Review of Vaccines, 2012
- Antigen depot is not required for alum adjuvanticityThe FASEB Journal, 2011
- Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adultsVaccine, 2011
- Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunityVaccine, 2011
- Global capacity for emerging infectious disease detectionProceedings of the National Academy of Sciences, 2010
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Towards an understanding of the adjuvant action of aluminiumNature Reviews Immunology, 2009
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza virusesTherapeutics and Clinical Risk Management, 2009
- Toll-like receptors and innate immunityNature Reviews Immunology, 2001